Table 2 Summary of clinicopathologic findings in the three clusters of uterine endometrioid carcinomas of no special molecular profile (NSMP-UEC).
From: Genomic landscape of endometrial carcinomas of no specific molecular profile
Cluster 1 (n, %) | Cluster 2 (n, %) | Cluster 3 (n, %) | All Cases (n, %) | |
|---|---|---|---|---|
Age median (n, min/max) | 63 (28–91) | 61 (36–79) | 65 (33–86) | 63 (28–91) |
Tumor FIGO stage | ||||
I | 58 (72.5%) | 63 (77.8%) | 43 (54.4%) | 164 (68.3%) |
II | 5 (6.2%) | 3 (3.7%) | 7 (8.9%) | 15 (6.25%) |
III | 13 (16.2%) | 7 (8.6%) | 15 (19%) | 35 (14.6%) |
IV | 4 (5%) | 8 (9.9%) | 14 (17.7%) | 26 (10.8%) |
Disease status | ||||
Disease free | 42 (52.5%) | 51 (63%) | 18 (22.8%) | 111 (46.3%) |
Persisted/ recurred/ progressed | 38 (47.5%) | 30 (37%) | 61 (77.2%) | 129 (53.7%) |
Survival status | ||||
Alive | 66 (82.5%) | 63 (77.8%) | 40 (50.6%) | 169 (70.4%) |
Deceased | 14 (17.5%) | 18 (22.2%) | 39 (49.4%) | 71 (29.6%) |
Tumor FIGO grade | ||||
Grade I–II | 69 (86.2%) | 69 (85.2%) | 55 (69.6%) | 193 (80.4%) |
Grade III | 11 (13.7%) | 12 (14.8%) | 24 (30.4%) | 47 (19.6%) |
Tumor myometrial invasion | ||||
Absent | 24 (30%) | 31 (38.3%) | 18 (22.8%) | 73 (30.4%) |
Superficial invasion cannot be excluded | 4 (5%) | 5 (6.2%) | 3 (3.8%) | 12 (5%) |
Present | 49 (61.2%) | 44 (54.3%) | 49 (62%) | 142 (59.2%) |
N/A | 3 (3.7%) | 1 (1.2%) | 9 (11.4%) | 13 (5.4%) |
Cervical stromal invasion | ||||
Absent | 67 (83.7%) | 69 (85.2%) | 51 (64.6%) | 187 (77.9%) |
Present | 10 (12.5%) | 9 (11.1%) | 19 (24%) | 38 (15.8%) |
N/A | 3 (3.7%) | 3 (3.7%) | 9 (11.4%) | 15 (6.2%) |
Lymphovascular invasion | ||||
Absent | 52 (65%) | 58 (71.6%) | 36 (45.5%) | 146 (60.8%) |
Present | 23 (28.7%) | 22 (27.2%) | 33 (41.8%) | 78 (32.5%) |
N/A | 5 (6.2%) | 1 (1.2%) | 10 (12.7%) | 16 (6.7%) |
